Receive the latest updates from Matrix Medical in real time to understand product information.

On October 2nd, a delegation of experts from the Biomedical Polymer Materials Branch of the Chinese Society for Biomaterials visited Hangzhou Matrix Medical Technology Co., Ltd. for in-depth exchanges on the company's development, industry university research, and future cooperation. The Biomedical Polymer Materials Branch of the Chinese Society for Biomaterials is a secondary branch under the Chinese Society for Biomaterials, aimed at uniting scientific and technological personnel across the country, promoting innovative research, technological development, and the transformation and application of achievements related to biomedical polymer materials.

The experts and scholars who visited Juzheng Medical this time include the founder, chairman, vice chairman, and committee members of the Polymer Materials Branch, all of whom are "big names" in the research fields of biomedical polymers, nanobiomaterials, etc. They are Gu Zhongwei, a member of the International Committee of the World Federation of Biomaterials Science and Engineering Societies, former Vice Chairman and Secretary General of the China Biomaterials Committee, and Chief Scientist of the 973 Program for three consecutive terms; Chen Xuesi, academician of the CAS Member, researcher, doctoral supervisor, member of the Party Committee, executive deputy director of the Academic Committee of the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, and deputy director of the Academic Committee of the Key Laboratory of Ecological and Environmental Polymer Materials, Chinese Academy of Sciences; Gan Zhihua, member of the Standing Committee of the Party Committee and Vice President of Beijing University of Chemical Technology, member of the Academic Committee of the Key Laboratory of Engineering Plastics, Chinese Academy of Sciences, and member of the Academic Committee of the Key Laboratory of Organic Functional Molecular Synthesis and Assembly Chemistry, Chinese Academy of Sciences; Shi Linqi, Director of the Institute of Polymer Chemistry at the School of Chemistry, Nankai University, Director of the Key Laboratory of Functional Polymer Materials of the Ministry of Education, and Vice Chairman of the Branch; Academician of the American Academy of Medical and Biological Engineering, expert in functional polymer synthesis and nanomedicine, distinguished professor at Zhejiang University, and Dean of the School of Chemical Engineering and Bioengineering at Zhejiang University, Shen Youqing; Professor Liu Wenguang from the School of Materials Science and Engineering, Tianjin University; Professor and doctoral supervisor at the University of Science and Technology of China, You Yezi; Sun Junqi, Dean of the Graduate School of Jilin University, Director, Professor and Doctoral Supervisor of the State Key Laboratory of Supramolecular Structure and Materials; Tian Huayu, School of Chemistry and Chemical Engineering, Xiamen University, and Nanjing University Distinguished Professor; Professor Mao Hongli from Nanjing University of Technology and specially appointed researcher at Guangdong Academy of Sciences; Associate Professor Ning Zhenbo from the School of Life Science and Technology, Beijing University of Chemical Technology; Luo Kui, a researcher and doctoral supervisor at West China Hospital of Sichuan University.

During the visit and exchange, Ji Peihong, the founder and general manager of Matrix, introduced the company's development, core product research and development, and other aspects. Matrix Medical has always adhered to the research and development concept of "intervention without implantation", committed to providing disruptive medical devices for the development of vascular intervention therapy, and providing new treatment methods for patients with cardiovascular and cerebrovascular diseases. Since its establishment in 2021, it has been awarded multiple honors such as National High tech Enterprise. Currently, several core products have entered the clinical and certificate application stages.

Academician Chen Xuesi shared his rich experience in industrialization, and he believes that the current development of the medical industry should not only solve the bottleneck problem, but also build confidence and truly achieve original innovation. Academician Chen highly appreciates our company's natural vascular stent products that have entered the clinical stage. He believes that they have broken the existing technological thinking and opened up a new research and development path. He also provided valuable opinions on the product and registration, stating that overcoming difficulties not only requires wisdom and courage, but also requires mutual cooperation between teams. Academician Chen stated that he will lead the team to fully support the development of Juzheng Medical.

Principal Gan Zhihua shared the main research directions of his team at present, believing that three types of vascular intervention medical devices are related to patient health. He hopes that Matrix Medical will work hard to provide high-quality products to domestic patients. At the same time, President Gan highly recognized the investment of Matrix Medical in the direction of industry university research, believing that our company is determined to transform the country's investment in basic research into industrialization, which not only meets the needs of the country, but also satisfies the original intention of scientists to further benefit humanity from scientific research achievements. Principal Gan also officially invited the Matrix team to Beijing for exchange and learning.

Professor Liu Wenguang shared the research direction of hydrogel and the experience of Tianjin University's industrialization, and expressed great affirmation of the direction in which Matrix Medical is engaged. He hoped that the two sides could further deepen their cooperation.

Accompanied by Wei Zhaohua, co-founder of Matrix Medical, the expert team also visited the company's work and experimental sites to understand the company's construction and research and development usage.